Generic Name: daclatasvir/asunaprevir/beclabuvir

Pronunciation: N/A

Abbreviation: DCV/ASV/BCV or DCV-TRIO

Other Market Name: N/A

Drug Class: Multi-Class Combination Drugs

Company: Bristol-Myers Squibb

Approval Status: Phase lll

Generic Version Available: No

Experimental Code: BMS 790052 + BMS 650032 + BMS 791325

Drug Indication

This drug regimen has not yet been FDA-approved or reviewed for inclusion in the AASLD/IDSA list of recommended HCV treatments.

General Info

  • This drug regimen is an experimental HCV medication, currently in Phase III clinical trials.
  • DCV-TRIO is a fixed-dose regimen containing one currently approved HCV medication (daclatasvir) and two experimental medications (asunaprevir and beclabuvir). Daclatasvir is an approved NS5A replication complex inhibitor; asunaprevir is an NS3 protease inhibitor; beclabuvir is a non-nucleoside NS5B polymerase inhibitor.
  • DCV-TRIO is being tested for the treatment of chronic hepatitis C infection in adults for genotypes 1, 4, and 6.


Adult Dose: In clinical trials, subjects received a twice-daily, fixed-dose regimen of daclatasvir (30 mg), asunaprevir (200 mg) and beclabuvir (75 mg).

Pediatric Dose: N/A

Dosing Info: N/A

Side Effects

The most common side effects reported in clinical trials were headache, diarrhea, fatigue and nausea.

Last Reviewed: March 5, 2019